Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - April 2014


2nd Biosimilars & Biobetters Congress

03 Apr 2014 - 04 Apr 2014 - London, UK



Bookmark and Share


Over  two days, the 2nd Annual Biosimilars and Biobetters Congress will attract over 175 senior decision makers from Europe and the US with a comprehensive conference program featuring two separate streams, keynote addresses, case study presentations and interactive panel discussions given by over 25 expert speakers from leading pharmaceutical, biotech, academic and research institutes. 

The congress features two streams:

Market Opportunities & Commercial Challenges: In Stream 1, the meeting will address the most pressing challenges in gaining access to emerging markets and branding biosimilars through a series of cutting-edge conference presentations. Our boisimilars experts will also debate how to overcome regulatory challenges, outsource manufacturing and develop pricing strategies

Developing Biosimilars & Biobetters:  Learn more about current developments in clinical trials, including pharmacovigilence and patient safety. Do not miss out on the chance to discover innovative solutions for achieving quality by design, demonstrating biosimilarity and addressing potency as well as the latest insights into the regulatory requirements and trial design. 

This meeting is the single most senior-level focused event in Europe, dedicated to key technological and scientific advances in the follow on biologics industry.


Contact Kathryn Randall to download the agenda and for attendance information on k.randall@oxfordgloabl.co.uk or call +44 (0)1865 248455



Further information
Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!